Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA Allies with Patients' Groups for Lobbying
December 13, 2010
- Astellas Establishes Global Oncology Strategy Unit
December 13, 2010
- Ain Pharmaciez: Half-Year Sales Up 3.5% to \61.8 Bil.
December 13, 2010
- Takeda Applies for Higher Leuplin Dosage Based on Published Evidence
December 13, 2010
- Shionogi Leads IP Assets Ranking Followed by Kyowa Kirin
December 6, 2010
- Kyowa Kirin to Present KW-0761 Results at ASH
December 6, 2010
- Janssen Resumes Supply of Velcade
December 6, 2010
- BI Publishes Dabigatran Sub-Group Analysis
December 6, 2010
- Popular Name Made Legal Name: InCROM
December 6, 2010
- OncoTherapy Starts Clinical Trial for Gastric Tumor Vaccine
December 6, 2010
- NHI Pricing Recommended for Xyzal, Byetta
December 6, 2010
- PAFSC Withholds Recommending Switch OTC Version of Epadel
December 6, 2010
- Memantine, Galantamine Recommended for Approval for AD
December 6, 2010
- Yasuchika Hasegawa to Be Appointed Chairman of Keizai Doyukai
December 6, 2010
- Takeda's SONIAS Recommended for Approval
December 6, 2010
- Kobayashi: Sales Up 0.8% despite Rebound from Boom for Flu-related Products in Previous Year
December 6, 2010
- Janssen's Stelara Recommended for Approval
December 6, 2010
- Cawachi: Sales, Profits Show Only Slight Increases
December 6, 2010
- 2-Week Limit on Prescription to Be Lifted for 4 ARB/CCB Combination Drugs
December 6, 2010
- Bayer Schering to Apply for Rivaroxaban in US, Europe by Year End: Chairman Andreas Fibig
December 6, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…